Skin Cancer News

Skin Cancer News

Study Investigates Association Between Height and Risk of Invasive Melanoma

Publish Date June 18, 2020

This study used data from the Nurses’ Health Study (NHS) and NHS2 to explore the association between height, number of nevi, and risk of invasive melanoma.

Melanoma Risk and Biologic Therapy: Is There a Link?

Publish Date June 16, 2020

Because the TNF-α pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.

Has the Time for At-Home Cancer Care Finally Come?

Publish Date June 10, 2020

A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.

Racial Differences Seen in Time to Treatment for Melanoma

Publish Date June 8, 2020

Time from diagnosis to definitive surgery is twice as long on average for black versus white patients.

No Solid Evidence to Support GEP Testing in Thin Melanoma

Publish Date May 20, 2020

Most studies that have looked at 31-GEP testing in melanoma have been retrospective or prospective, and did not involve a comparator group.

Neoadjuvant Nivolumab Appears Promising in Merkel Cell Carcinoma

Publish Date May 19, 2020

A small phase 1/2 study shows high pCR rates.

A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials

Publish Date May 13, 2020

The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.

Exposure to Antibiotics Associated With Survival Detriment in Patients With Advanced Melanoma Treated With ICIs

Publish Date May 6, 2020

Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.

Continuous Dosing of BRAF/MEK Inhibition Superior to Intermittent Dosing in Melanoma

Publish Date April 27, 2020

Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.

Atezolizumab Plus BRAF/MEK Inhibition Prolonged PFS in Melanoma

Publish Date April 27, 2020

Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.

Keratinocyte Carcinoma Risk Factors in Allogeneic Hematopoietic Cell Transplant Recipients

Publish Date April 22, 2020

Although allogeneic HCT is associated with increased risk for keratinocyte carcinoma, the magnitude of risk linked to certain patient characteristics is still unknown.

Thyroid Dysfunction During Anti–PD‐1 Immunotherapy Linked to Better Survival Outcomes

Publish Date April 17, 2020

There was no increase in survival linked to acquired subclinical thyroid dysfunction or preexisting thyroid dysfunction, however.

Model Could Help Identify Who May Respond to Checkpoint Inhibition in Melanoma

Publish Date April 17, 2020

Imaging radiomics and blood markers could differentiate pseudoprogression.

NBUVB Phototherapy May Not Increase Skin Cancer Risk in Patients With Vitiligo

Publish Date April 14, 2020

Many patients with vitiligo undergo multiple courses of phototherapy, which may raise concerns about their risk of photocarcinogenesis.

Selumetinib Deemed Effective in Pediatric Inoperable Plexiform Neurofibromas

Publish Date April 2, 2020

A phase 2 trial demonstrated tumor shrinkage and improvement in reported outcomes in children with inoperable plexiform neurofibromas associated with neurofibromatosis type 1.

Minority of Melanomas With Complete Response to Anti–PD-1 Relapsed After Drug Cessation

Publish Date March 23, 2020

More research is needed to define criteria for stopping therapy.

Hydrochlorothiazide Exposure May Be Associated With Increased Risk of Nonmelanoma Skin Cancer

Publish Date March 12, 2020

In this study, oral cancer risk was used as a negative control since it is not associated with increased exposure to UV radiation.

What Contributed to the Decrease in Melanoma Incidence in Younger Individuals?

Publish Date March 6, 2020

A recent study documents a downward trend in melanoma incidence in adolescents and young adults, but experts disagree about the causes.

A New Trend in Drug Development: Leveraging Data from Expanded Access

Publish Date March 2, 2020

Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.

Evidence Suggests B Cells Play a Role in Immunotherapy Response

Publish Date February 24, 2020

New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.